Navegando por Palavras-chave "hepatocellular carcinoma"
Agora exibindo 1 - 5 de 5
Resultados por página
Opções de Ordenação
- ItemSomente MetadadadosApoptosis, PCNA and p53 in hepatocellular carcinoma(H G E Update Medical Publishing S A, 2002-07-01) Paiva, C.; Oshima, Celina Tizuko Fujiyama [UNIFESP]; Lanzoni, Valeria Pereira [UNIFESP]; Forones, Nora Manoukian [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)Background/Aims: The regulation of cell number is present in normal tissues but is lost in malignant neoplasms. The real :meaning of these alterations is not well known. Apoptosis is the programmed cell death. p53, a tumor supressor gene, has an important function in DNA repair and in regulation of apoptosis. Mutations of p53 were described in malignant tumors and can be the cause of the alterations of this balance. Proliferating cell nuclear antigen is an auxiliary protein present during G1-late phase and S phase.The aim of this study was to compare cell proliferation, apoptosis and expression of p53 in hepatocellular carcinoma.Methodology: Fifteen patients with hepatocellular carcinoma were included. Ten patients were men. The mean age of the patients was 55.53 years old. Cirrhosis was positive in nine patients, 5 were HBsAg positive and none were anti-HCV positive. The mean level of AST and ALT were respectively, 62.79 and 50.64. Formalin-fixed and paraffin-embedded tissues from these patients were examined retrospectively. Apoptosis were measured by counting the number of apoptotic bodies in 500 tumoral cells. The expression of p53 oncogene and the PCNA were determined by immunohistochemical method, using avidin-biotin method (DAKO). The p53 were considered positive when the number of positive nuclei was more than 5% of the tumoral cells. The proliferative activity was determined by proliferating cell nuclear antigen labeling index.Results: The proliferating cell nuclear antigen-labeling index ranged from 0.48 and 0.95 (mean: 0.82). The p53 was positive in five patients. The number of apoptotic bodies counted ranged from 0 to 15 (mean: 4.20). There were no differences among p53 and the mean levels of proliferating cell nuclear antigen labeling index or p53 and the number of apoptotic bodies.Conclusions: A high index of proliferation has been shown in the patients studied. Positivity of p53 was seen in less than a half of the patients (35.71%). The index of apoptotic bodies observed was very low. Our results suggest that high-grade proliferation is not associated with increase of apoptosis in hepatocellular carcinoma.
- ItemAcesso aberto (Open Access)Hemorrhagic cerebral metastasis as a first manifestation of a hepatocellular carcinoma: case report(Academia Brasileira de Neurologia - ABNEURO, 1998-09-01) Peres, Mario Fernando Prieto [UNIFESP]; Forones, Nora Manoukian [UNIFESP]; Malheiros, Suzana Maria Fleury [UNIFESP]; Ferraz, Henrique Ballalai [UNIFESP]; Stávale, João Norberto [UNIFESP]; Gabbai, Alberto Alain [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)We report herein a rare instance in which a patient presented with a hemorrhagic cerebral metastasis as the initial manifestation of a hepatocellular carcinoma (HCC). A few cases of cerebral metastasis from HCC have been reported in the literature, mainly from eastern countries. This is the first report from South America of a cerebral metastasis from hepatocellular carcinoma.
- ItemSomente MetadadadosHepatitis G virus infection in patients with hepatocellular carcinoma in Recife, Brazil(Oxford Univ Press, 2007-08-01) Leão-Filho, Gustavo Carneiro; Lopes, Edmundo P. A.; Ferraz, Alvaro Antonio B.; Moura, Izolda; Pernambuco, J. Ricardo; Reis, Cynthia [UNIFESP]; Silva, Antônio Eduardo B. [UNIFESP]; Ferraz, Maria Lucia G. [UNIFESP]; Universidade Federal de Pernambuco (UFPE); Universidade Federal de São Paulo (UNIFESP)The evidence of a higher incidence of hepatitis G virus (HGV) infection among patients with hepatocellular carcinoma (HCC) and the relatively high prevalence of patients with primary liver carcinoma without apparent risk factors in our country motivated the present study, the objective of which was to determine the frequency of HGV-ribonucleic acid (RNA) in a series of patients with HCC. the diagnosis of HCC was established based on a-fetoprotein levels (>400 ng/ml), a compatible image and/or biopsy of the hepatic nodules. Markers of hepatitis B virus (HBV) (HBsAg and anti-HBc), hepatitis C virus (HCV) (anti-HCV) and HGV (HGVRNA) were investigated using MEIA and RT-PCR (reverse transcriptase polymerase chain reaction). There were 32 patients evaluated, including 20 males (63%), with a mean age of 58 years. Twenty-eight (88%) patients were cirrhotic (Child-Pugh: A = 8 patients, B = 14, and C = 6) and 50% reported alcohol consumption. Serological hepatitis markers were detected in 26 (81%) patients, including HBV in 19 (59%), HCV in 12 (38%) and HGV in 9 (28%). Only one (3%) patient was positive for HGV alone. the prevalence of HGV in blood donors from the same region is 10%. the findings suggest that, despite the frequent detection of HGV markers in patients with HCC, isolated infection with this agent does not seem to be a relevant factor in the etiology of this carcinoma.
- ItemSomente MetadadadosHepatocellular carcinoma in association with bile duct hamartomas: report on 2 cases and review of the literature(Elsevier B.V., 2008-06-01) Heinke, Thais [UNIFESP]; Pellacani, Lucila Bohme [UNIFESP]; Oliveira Costa, Henrique de [UNIFESP]; Fuziy, Rogerio Aoki [UNIFESP]; Franco, Marcello [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)Biliary hamartomas are hepatic lesions related to defects in the ductal plate and are part of the spectrum of adult polycystic disease. Microscopically, the lesions are small and consist of irregular bile ducts amidst a fibrous stroma. There are reports on the malignant transformation of biliary hamartomas, particularly on cholangiocarcinoma. Case 1: a 19-year-old woman presented with increased abdominal volume, lumbar pain, jaundice, choluria, cachexia, and progression to hepatic insufficiency. At autopsy, the liver weighed 8850 g and showed a 20.5-cm mass in the right lobe and nodules in the left lobe. Case 2: a 39-year-old man presented with an asymptomatic nodule in the right hepatic lobe. A 6.5-cm liver segment containing a 3.0-cm nodule was excised. Histopathology of both cases revealed hepatocelluar carcinoma associated with multiple bile duct hamartomas (von Meyenburg complex). Bile duct hamartoma is generally and incidental finding at laparotomy and autopsy because its course is asymptomatic. the literature has documented its possible progression to malignant neoplasia. However, this relationship has only been established with cholangiocarcinomas. We report herein for the first time on the association of the lesion with hepatocellular carcinoma. (C) 2008 Elsevier Inc. All rights reserved.
- ItemSomente MetadadadosPlasma Lipidomic Fingerprinting to Distinguish among Hepatitis C-related Hepatocellular Carcinoma, Liver Cirrhosis, and Chronic Hepatitis C using MALDI-TOF Mass Spectrometry: a Pilot Study(Medical Univ Press, 2015-03-01) Passos-Castilho, Ana Maria [UNIFESP]; Lo Turco, Edson [UNIFESP]; Ferraz, Maria Lucia [UNIFESP]; Matos, Carla [UNIFESP]; Silva, Ivonete [UNIFESP]; Parise, Edison [UNIFESP]; Pilau, Eduardo; Gozzo, Fabio; Granato, Celso [UNIFESP]; Universidade Federal de São Paulo (UNIFESP); Universidade Estadual de Campinas (UNICAMP); Univ MaringaBackground & Aims: Hepatitis C (HC) is a major cause of hepatocellular carcinoma (HCC), and a late diagnosis is the main factor for the poor survival of patients. There is an urgent need for identifying sensitive and specific biomarkers for HCC diagnosis. In the present study, plasma lipid patterns of patients with HCHCC, HC-liver cirrhosis (LC), and chronic HC (CHC) were assessed by matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS).Methods. Plasma samples of 25 patients with HC-HCC, 15 patients with HC-LC, and 25 patients with CHC were evaluated by MALDI-MS using a Q-ToF premier (Synapt) mass spectrometer (Waters, Manchester, UK) equipped with a 200-Hz solid-state laser in the mass range between m/z (mass-to-charge ratio) of 700-1200.Results. A total of 2205 ions were initially obtained and 7 ions (m/z) were highlighted as corresponding to the most important lipids to differentiate HCC patients from LC and CHC patients. The specific lipidomic expression signature generated resulted in an overall predictive accuracy of 93% of HC-HCC and HC-LC, and 100% of HC-HCC and CHC. The 7-peak algorithm distinguished HCC from LC with a sensitivity of 96% and a specificity of 87%, and HCC from CHC with both sensitivity and specificity of 100%.Conclusion. MALDI-MS-specific signature peaks accurately distinguished patients with HC-HCC from those with FIC-LC and CHC. The results indicate the potential of MALDI-MS and the selected peaks to improve HCC surveillance in patients with viral C cirrhosis and chronic hepatitis C.